Co - development and co - commercialization
Search documents
信达生物_IBI363 与 IBI343 达成 110 亿美元巨额交易；武田制药作为亚太到全球的引领者
2025-10-23 02:06
23 October 2025 | 8:38AM HKT Equity Research Innovent Biologics (1801.HK): US$11bn mega deal on IBI363/IBI343; Takeda as the Asia-to-global guide +852-2978-0526 | ziyi.chen@gs.com Goldman Sachs (Asia) L.L.C. Linhai Zhao, Ph.D. +852-3966-4059 | linhai.zhao@gs.com Goldman Sachs (Asia) L.L.C. c45a43530f604d12bcb9a82b5aa6b9f6 Goldman Sachs Innovent Biologics (1801.HK) US$11.4bn mega deal with Takeda on IBI363/IBI343: On Oct 22, Innovent announced a global strategic collaboration with Takeda Pharmaceuticals (cov ...